Dr. Nic James Mastascusa is a pharmacist who is specialized in Nuclear in Cedar Rapids, Iowa. Patients can reach him at 83 16th Ave Sw, Cedar Rapids or contact him on 319-363-4425. Active license number of Dr. Nic James Mastascusa is 20846 for Nuclear in Iowa. Dr. Nic James Mastascusa is a licensed pharmacist who has demonstrated specialized knowledge and skill in procurement, compounding, quality control testing, dispensing, distribution, and monitoring of radiopharmaceuticals.
Complete Profile:
Dr. Nic James Mastascusa speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Nic James Mastascusa
Specialization:
Nuclear
Credentials:
PHARMD
Gender:
Male
Location:
83 16th Ave Sw, Cedar Rapids, Iowa, 52404-5948
Phone:
319-363-4425
Fax:
319-363-5112
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Nic James Mastascusa are as mentioned below.
NPI Number:
1609202076
NPI Enumeration Date:
17 Sep, 2013
NPI Last Update On:
17 Sep, 2013
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Nic James Mastascusa are as mentioned below.
Specialization
License Number
State
Status
Nuclear
20846
Iowa
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
83 16th Ave Sw, Cedar Rapids, Iowa
Zip:
52404-5948
Phone Number:
319-363-4425
Fax Number:
319-363-5112
Patients can reach Dr. Nic James Mastascusa at 83 16th Ave Sw, Cedar Rapids, Iowa or can call on phone at 319-363-4425.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.